Business
Microbix to Present at Rodman & Renshaw Investor Healthcare Conference. Management to Highlight Pipeline Opportunities.
/NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED ...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"\n\n\n\n/NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR\nDISSEMINATION IN THE UNITED STATES/\n\n\nTORONTO, Sept. 3 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) announced\ntoday that the Company's Chief Business Officer and Director, Mark Cochran,\nPhD, will present at Rodman & Renshaw's 11th Annual Healthcare Conference to\nbe held at the New York Palace Hotel in New York City September 9 - 11th. The\npresentation will take place on Friday, September 11th at 3:40 p.m. in the\nHenry Room.\n\n\nA webcast of the presentation will be available live and archived at\nhttp://microbix.com.\n\n\nMicrobix specializes in the development of biological technologies and\ncommercializing them through global partners. The Company has intellectual\nproperty in large market biotherapeutic drugs, vaccine technologies and animal\nreproduction technologies. Established in 1988, Microbix is headquartered in\nToronto.\n\n\nThis news release is intended for distribution in Canada only and is not\nintended for distribution to United States newswire services or dissemination\nin the United States. The securities being offered have not been, nor will\nthey be registered under the United States Securities Act of 1933, as amended,\nand may not be offered or sold within the United States or to, or for the\naccount or benefit of, U.S. persons absent U.S. registration or an applicable\nexemption from the U.S. registration requirements. This release does not\nconstitute an offer for sale of securities in the United States.\n\n\nThis press release contains forward-looking statements, which are subject\nto risks and uncertainties that could cause actual results to differ\nmaterially from those set forth in the forward-looking statements including\nthe risks associated with failure to get authorization to release Kinlytic for\ndistribution in the US from the FDA, inability to complete financing for the\nHunan China project currently the subject of financing; risks associated with\ncommercializing the pipeline technologies; risks associated with failure to\ndevelop and commercialize SST; non-adoption of SST; risks associated with\ncurrency exchange rates which may exaggerate or reduce the actual financial\nperformance of the Company. These forward-looking statements represent the\nCompany's judgment as of the date of this press release. The C...